ProKidney to Participate in the Guggenheim Inaugural Healthcare Innovation Conference and the Jefferies London Healthcare Conference

Company Overview - ProKidney Corp. is a late clinical-stage biotech company focused on developing a first-in-class cell therapy candidate for chronic kidney disease (CKD) [1] - The company was founded in 2015 and has a decade of research behind it [6] - ProKidney's lead product candidate, rilparencel (REACT®), is an autologous cellular therapy being evaluated in Phase 2 and Phase 3 studies for preserving kidney function in diabetic patients at high risk of kidney failure [6] - Rilparencel has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA [6] Upcoming Events - ProKidney management will participate in two healthcare conferences in November 2024 [1] - The first event is the Guggenheim Inaugural Healthcare Innovation Conference in Boston on November 13, 2024, at 10:30 am ET [3] - The second event is the Jefferies London Healthcare Conference on November 20, 2024, at 10:00 am GMT [4] - Live webcasts of these events will be accessible through the "Events" section of ProKidney's website, with replays available for 90 days post-event [4] Investor Engagement - ProKidney management will host one-on-one meetings during the conferences [5] - Interested investors are encouraged to contact their Guggenheim and Jefferies representatives to schedule meetings [5]